# US 2003/0206944 A1 · Wound dressings with elastase-sequestering

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0206944 A1
- Document ID: US20030206944A1
- Status: Published application
- Kind: A1
- Application number: 10/446,806
- Filed: 2003-05-29
- Published: 2003-11-06
- Earliest claimed: 2000-02-29
- Inventors: Kelman I. Cohen; Robert F. Diegelmann; Dorne Yager; Judson Vincent Edwards
- Web page: https://patentgrep.com/patent/US20030206944A1

## CPC

- A61L 15/44: Medicaments
- A61L 15/28: Polysaccharides or their derivatives {(A61L15/225 takes precedence)}
- A61L 2300/434: of enzymes
- Y10T 442/2525: Coating or impregnation functions biologically [e.g., insect repellent, antiseptic, insecticide, bactericide, etc.]
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The invention provides wound dressings and methods of their use, especially for the treatment of chronic, non-healing wounds. The wound dressings are composed of a support matrix, such as cotton cellulose, and an active agent associated with the support matrix. The active agent may be a protease inhibitor or a protease sequestrant, in particular an inhibitor or sequestrant of a neutrophil-derived cationic protease such as elastase.

## Claims

### Claim 1

A method for sequestering elastase at a wound site comprising the step of contacting said wound site with a wound dressing selected from the group consisting of carboxymethylcellulose, dialdehyde gauze, sulfonated gauze, and phosphorylated gauze.

### Claim 2 (depends on 1)

The method of claim 1 wherein said wound dressing is carboxymethylcellulose.

### Claim 3 (depends on 1)

The method of claim 1 wherein said wound dressing is dialdehyde gauze.

### Claim 4 (depends on 1)

The method of claim 1 wherein said wound dressing is sulfonated gauze.

### Claim 5 (depends on 1)

The method of claim 1 wherein said wound dressing is phosphorylated gauze.

### Claim 6

A wound dressing for treating a wound, comprising
a support matrix, and
an active agent associated with said support matrix, wherein said active agent is selected from the group consisting of an inhibitor of a neutrophil-derived protease and a protease sequestrant.

### Claim 7 (depends on 6)

The wound dressing of claim 6 wherein said support matrix is selected from the group consisting of cellulose and carboxymethylcellulose.

### Claim 8 (depends on 6)

The wound dressing of claim 6 wherein said neutrophil-derived protease is elastase.

### Claim 9 (depends on 6)

The wound dressing of claim 6 wherein said inhibitor is selected from the group consisting of Val—Pro—Val, Val—Pro—Val-O Methylester, Ala—Ala—Pro—Val-chloromehylketone, Ala—Ala—Pro—Val-pentafluoroethylketone, propyl-3-ketone, glucose-6-citrate, and levulinate.

### Claim 10 (depends on 6)

The wound dressing of claim 6 wherein said protease sequestrant is selected from the group consisting of aldehyde, sulfate and phosphate.

### Claim 11 (depends on 6)

The wound dressing of claim 6 wherein said active agent is associated with said support matrix by a means selected from the group consisting of covalent bonding, non-covalent bonding and ionic bonding.

### Claim 12 (depends on 6)

A method for enhancing would healing, comprising,
contacting said wound with the wound dressing of claim 6.

### Claim 13 (depends on 12)

The method of claim 12 wherein said wound is chronic.
